GGrantIndex
← Search

ORAL CALCIMIMETIC AGENT AMG-073 IN HYPERPARATHYROIDISM

$0M01FY2000RRNIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications & trials

Abstract

Our hypothesis is that the calcimimetic drug, AMG 073, will safely lower parathyroid hormone and calcium blood levels in patients with primary hyperparathyroidism. The specific aim of this study is to assess the clinical effects, safety and pharmacokinetics of daily oral doses of AMG 073 for six weeks in patients with primary hyperparathyroidism.

View original record on NIH RePORTER →
ORAL CALCIMIMETIC AGENT AMG-073 IN HYPERPARATHYROIDISM · GrantIndex